EPS for Rhythm Pharmaceuticals, Inc. (RYTM) forecasted at $-0.45

May 17, 2018 - By Edith Ladford

Investors expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)’s quarterly earnings on June, 11., according to RTT. 9.76 % negative EPS growth is what Wall Street’s forecasts after $-0.41 reported EPS previous quarter. RYTM reached $30.78 during the last trading session after $0.94 change.Rhythm Pharmaceuticals, Inc. has 145,865 shares volume, 44.87% up from normal. RYTM is and has moved 0.00% since May 17, 2017. RYTM underperformed by 11.55% the S&P500.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States.The firm is worth $847.00 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.Currently it has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were posted by Nasdaq.com, Globenewswire.com and Nasdaq.com. The first one has “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” as a title and was posted on May 09, 2018. The next is “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results” on May 14, 2018. And last was posted on May 09, 2018, called “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference”.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.